✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Status◇ research
Acquired
Exit Type◇ research
Acquisition
Subsequent Funding◇ research
—
Received VC Funding◇ research
—
Current Employees◇ research
0
Peak Employees◇ research
15
SBIR/STTR Awards◇ research
$3,700,000
Filed Form D◇ research
No
Used Crowdfunding◇ research
No
Notes
Transposagen shows evidence of earlier federal SBIR support and later technology/IP acquisition by Lonza. The strongest public signals point to the piggyBac-related IP being acquired in 2019, but the precise legal-entity closeout deserves a second-pass check.
[Deep research 2026-04-11] Company operated from multiple Lexington addresses including 201 West Second St., 203 W 2nd St. Ste 1, and 535 West Second St. Had exclusive marketing/distribution agreement with Charles River Laboratories pre-2019. Focused on genetically modified rodent models for drug discovery using piggyBac technology. Peak employee count confirmed at 15 per SBIR records. No USPTO patents or SEC Form D filings identified. Website transposagenbio.com shows legacy products but no current activity.
Last updated: Apr 11, 2026 · Evidence score: 5/5